omics.co.in logo omics.co.in

Chapter 5: Precision Oncology: Driver Mutations, Oncogenes & Tumor Suppressors

1 min read • Verified October 2026 • Peer-Reviewed Learning Resource
Tested Stacks: GATK 4.6.1 Samtools 1.21 Nextflow 24.10 Seurat v5.1 Python 3.12
Prerequisites: Basic Linux CLI & Sequencing Formats
📚 Chapter 5 of 13 0% Course Completed

Chapter 5: Precision Oncology: Driver Mutations, Oncogenes & Tumor Suppressors

Cancer is an evolutionary disease driven by somatic mutations that confer selective growth and survival advantages to neoplastic cells. Precision oncology identifies these specific driver mutations to match cancer patients with targeted kinase inhibitors, antibody-drug conjugates, or immunotherapies.

Oncogenes vs. Tumor Suppressor Genes
  • Proto-Oncogenes (Activating Drivers): Require only a single activating hit (dominant). Mutations cluster at specific amino acid hotspots (e.g. KRAS G12D/V, BRAF V600E, PIK3CA H1047R) or cause focal copy-number amplifications (e.g. ERBB2 / HER2 amplification).
  • Tumor Suppressor Genes (Loss of Function): Follow Knudson's two-hit hypothesis (recessive). Mutations are distributed across the entire gene body (frameshifts, nonsense mutations, deletions, or epigenetic silencing in TP53, PTEN, RB1, BRCA1/2).

1. The AMP/ASCO/CAP Somatic Variant Tiers

Unlike the ACMG germline 5-tier system, somatic oncology classifies variants based on clinical actionability:

# Somatic Clinical Actionability Tiers (AMP/ASCO/CAP):
# -----------------------------------------------------------------------------------------
# Tier       Clinical Significance                   Therapeutic Actionability
# -----------------------------------------------------------------------------------------
# Tier I     Strong Clinical Significance            FDA-approved therapy (Level A) or 
#                                                    well-powered professional guideline (Level B)
# Tier II    Potential Clinical Significance         FDA-approved in another cancer type (Level C)
#                                                    or ongoing clinical trials (Level D)
# Tier III   Uncertain Clinical Significance (VUS)   Unknown functional or clinical impact
# Tier IV    Benign or Likely Benign                 High population frequency; non-actionable
# -----------------------------------------------------------------------------------------
⚠️

Common Pitfalls & Troubleshooting Checklist

  • Java Heap Exhaustion (GATK / Picard): If processes terminate with java.lang.OutOfMemoryError, set your environment variable explicitly: export _JAVA_OPTIONS="-Xmx16g -Djava.io.tmpdir=/tmp".
  • Index Timestamp Mismatch: If tools complain that a BAM index is missing or out of date, regenerate with samtools index -@ 4 sample.bam.
  • Conda Channel Conflicts: Avoid ABI incompatibilities between bioconda and conda-forge by setting strict priority: conda config --set channel_priority strict.
  • Chromosome Naming Contamination: Always verify whether reference FASTA headers use chr1 or 1; divergent naming causes silent alignment drops.
Was this guide helpful to your research?
Help us maintain 100% accurate, peer-reviewed bioinformatics standards.
📝 Propose Edit on GitHub ↗